Why the study?
Cardiac contractility modulation has emerged as a promising device treatment for HF in patients not indicated for cardiac resynchronization therapy, warranting a comprehensive individual patient data meta-analysis of functional capacity and quality of life.
Does cardiac contractility modulation improve functional capacity and quality of life in heart failure patients not indicated for cardiac resynchronization therapy?
Population
Patients with HF not indicated for CRT across 5 trials
Comparison
CCM vs control
Design
Individual patient data meta-analysis of prospective randomized controlled trials and one single-arm trial
Authors
Loading...
May warrant consideration in CRT-ineligible HFrEF; leaves open effects on hospitalization and survival.
Does cardiac contractility modulation improve functional capacity and quality of life in heart failure patients not indicated for cardiac resynchronization therapy?
Cardiac contractility modulation provides statistically significant and clinically meaningful benefits in functional capacity and heart failure-related quality of life in patients not indicated for cardiac resynchronization therapy.
Giallauria et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: